Placebo controlled trials in neuromyelitis optica are needed and ethical

Multiple Sclerosis and Related Disorders

Volumn 4, Issue 6, 2015, Pages 536-545

  Cree, Bruce A C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aquaporin 4; Clinical trial; Devic's disease; Equipoise; Ethics; Neuromyelitis optica; Placebo control

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ECULIZUMAB; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MYCOPHENOLATE MOFETIL; NATALIZUMAB; PLACEBO; PLASMA SUBSTITUTE; PREDNISONE; RITUXIMAB; TOCILIZUMAB; IMMUNOLOGIC FACTOR;

CLINICAL DECISION MAKING; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DRUG EFFICACY; EQUIPOISE; EVIDENCE BASED MEDICINE; HEALTH CARE QUALITY; HUMAN; METHODOLOGY; MYELOOPTIC NEUROPATHY; PATIENT HARM; PATIENT PARTICIPATION; PATIENT RISK; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; RESEARCH ETHICS; REVIEW; RISK BENEFIT ANALYSIS; ETHICS; NEUROMYELITIS OPTICA;

CONTROLLED CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOLOGIC FACTORS; NEUROMYELITIS OPTICA;

EID: 84947569383     PISSN: 22110348     EISSN: 22110356     Source Type: Journal    
DOI: 10.1016/j.msard.2015.07.017     Document Type: Review

References (71)

1. (http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/050722s021,050723s019,050758s019,050759s024lbl.pdf), accessed February 23, 2014c.
2. (http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/103705s5311lbl.pdf), accessed February 23, 2014d.
3. (http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/016324s034s035lbl.pdf), accessed February 23, 2014b.
4. (http://www.wma.net/en/30publications/10policies/b3/), accessed February 23, 2014a.
5. M. Araki, T. Matsuoka, K. Miyamoto, S. Kusunoki, T. Okamoto, M. Murata, S. Miyake, T. Aranami, and T. Yamamura Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study Neurology 82 2014 1302 1306
6. N. Asgari, S.T. Lillevang, H.P. Skejoe, M. Falah, E. Stenager, and K.O.A. Kyvik Population-based study of neuromyelitis optica in Caucasians Neurology 76 18 2011 1589 1595
7. G.S. Bedi, A.D. Brown, S.R. Delgado, and et al. Impact of rituximab on relapse rate and disability in neuromyelitis optica Mult. Scler. J. 17 2011 1225 1230
8. D.B. Bichuetti, and E.M.L. de Oliveira Comment on neuromyelitis optica: potential roles for intravenous immunoglobulin J. Clin. Immunol. 33 2013 307
9. D.B. Bichuetti, E.M.L. Oliveira, F.C. Boulos, and A.A. Gabbai Lack of response to pulse cyclophosphamide in neuromyelitis optica: evaluation of 7 patients Arch. Neurol. 69 2012 938 939
10. D.B. Bichuetti, E.M.L. de Oliveira, D.M. Oliveira, N.A. de Souza, and A.A. Gabbai Neuromyelitis optica treatment: analysis of 36 patients Arch. Neurol. 67 2010 1131 1136
11. E. Bizzoco, F. Lolli, A.M. Repice, B. Hakiki, M. Falcini, A. Barilaro, R. Taiuti, G. Siracusa, M.P. Amato, T. Biagioli, S. Lori, M. Moretti, A. Vinattieri, P. Nencini, L. Massacesi, and S. Matà Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution J. Neurol. 256 11 2009 1891 1898
12. R. Bomprezzi, E. Postevka, D. Campagnolo, and T.L. Vollmer A review of cases of neuromyelitis optica Neurol. 17 2011 98 104
13. P. Cabre, S. Olindo, R. Marignier, and et al. Under the Aegis of the French National Observatory of Multiple Sclerosis: efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study J. Neurol. Neurosurg. Psychiatry 84 2013 511 516
14. J.A. Cohen, F. Barkhof, G. Comi, H.P. Hartung, B.O. Khatri, X. Montalban, J. Pelletier, R. Capra, P. Gallo, G. Izquierdo, K. Tiel-Wilck, A. de Vera, J. Jin, T. Stites, S. Wu, S. Aradhye, and L. Kappos Transforms study group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis New Engl. J. Med. 362 5 2010 402 415
15. A.J. Coles, C.L. Twyman, D.L. Arnold, J.A. Cohen, C. Confavreux, E.J. Fox, H.P. Hartung, E. Havrdova, K.W. Selmaj, H.L. Weiner, T. Miller, E. Fisher, R. Sandbrink, S.L. Lake, D.H. Margolin, P. Oyuela, M.A. Panzara, D.A. Compston, and CARE-MS II investigators Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial Lancet 9856 2012 1829 1839
16. C. Costanzi, M. Matiello, C.F. Lucchinetti, and et al. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica Neurology 77 2011 659 666
17. B.A.C. Cree, S. Lamb, K. Morgan, and et al. An open label study of the effects of rituximab in neuromyelitis optica Neurology 64 2005 1270 1272
18. D.S. Echt, P.R. Liebson, L.B. Mitchell, R.W. Peters, D. Obias-Manno, A.H. Barker, D. Arensberg, A. Baker, L. Friedman, H.L. Greene, and et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial New Engl. J. Med. 324 12 1991 781 788
19. L. Elsone, J. Kitley, S. Luppe, D. Lythgoe, K. Mutch, S. Jacob, R. Brown, K. Moss, B. McNeillis, Y.Y. Goh, M.I. Leite, N. Robertson, J. Palace, and A. Jacob Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK Mult. Scler. 20 2014 1533 1540
20. C.R. Freed, P.E. Greene, R.E. Breeze, W.Y. Tsai, W. DuMouchel, R. Kao, S. Dillon, H. Winfield, S. Culver, J.Q. Trojanowski, D. Eidelberg, and S. Fahn Transplantation of embryonic dopamine neurons for severe Parkinson's disease New Engl. J. Med. 344 10 2001 710 719
21. B. Freedman Equipoise and the ethics of clinical research New Engl. J. Med. 317 1987 141 145
22. B. Freedman Placebo-controlled trials and the logic of clinical purpose IRB 12 6 1990 1 6
23. G. Galindo-Rodriguez, A. Avina-Zubieta, S. Pizarro, and et al. Cyclophosphamide pulse therapy in optic neuritis due to systemic lupus erythematosus: an open trial Am. J. Med. 106 1999 65 69
24. V. Gredler, S. Mader, K. Schanda, and et al. Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases J. Neurol. Sci. 328 2013 77 82
25. R. Gross Levels of evidence: taking neurology to the next level Neurology 72 2009 8 10
26. S.Y. Huh, S.H. Kim, J.W. Hyun, A.R. Joung, M.S. Park, B.J. Kim, and H.J. Kim Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder JAMA Neurol. 71 2014 1372 1378
27. S. Hulley, D. Grady, T. Bush, C. Furberg, D. Herrington, B. Riggs, and E. Vittinghoff Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women heart and estrogen/progestin replacement study (HERS) research group JAMA 280 7 1998 605 613
28. V.H.L. Ip, A.Y.L. Lau, L.W.C. Au, and et al. Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders J. Neurol. Sci. 324 2013 38 39
29. A. Jacob, B.G. Weinshenker, I. Violich, and et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients Arch. Neurol. 65 2008 1443 1448
30. A. Jacob, M. Matiello, B.G. Weinshenker, and et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients Arch. Neurol. 66 2009 1128 1133
31. A. Jacob, J. Panicker, D. Lythgoe, L. Elsone, K. Mutch, M. Wilson, K. Das, and M. Boggild The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom J. Neurol. 260 8 2013 2134 2137
32. S. Jarius, and B. Wildemann AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance Nat. Rev. Neurol. 6 7 2010 383 392
33. S. Jarius, F. Aboul-Enein, P. Waters, and et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica Brain 131 2008 3072 3080
34. T. Kageyama, M. Komori, K. Miyamoto, and et al. Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica J. Neurol. 260 2013 627 634
35. S.-H. Kim, W. Kim, M.S. Park, and et al. Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica Arch. Neurol. 68 2011 473 479
36. S.-H. Kim, W. Kim, X.F. Li, I.-J. Lung, and H.J. Kim Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years Arch. Neurol. 68 2011 1412 1420
37. D.J. Kimbrough, K. Fujihara, A. Jacob, M.A. Lana-Peixoto, M.I. Leite, M. Levy, R. Marignier, I. Nakashima, J. Palace, J. de Seze, O. Stuve, S.N. Tenembaum, A. Traboulsee, E. Waubant, B.G. Weinshenker, D.M. Wingerchuk, and GJCF-CC&BR Treatment of neuromyelitis optica: review and recommendations Mult. Scler. Relat. Disord. 1 4 2012 180 187
38. J. Kitley, L. Elsone, J. George, and et al. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies J. Neurol. Neurosurg. Psychiatry 84 2013 918 921
39. J. Kleiter, K. Hellwig, A. Berthele, and et al. For the neuromyelitis optica study group: failure of natalizumab to prevent relapses in neuromyelitis optica Arch. Neurol. 69 2012 239 245
40. L.B. Krupp, C. Christodoulou, P. Melville, W.F. Scherl, L.Y. Pai, L.R. Muenz, D. He, R.H. Benedict, A. Goodman, S. Rizvi, S.R. Schwid, B. Weinstock-Guttman, H.J. Westervelt, and H. Wishart Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis Neurology 76 17 2011 1500 1507
41. J.W. Lindsey, K.M. Meulmester, S.A. Brod, F. Nelson, and J.S. Wolinsky Variable results after rituximab in neuromyelitis optica J. Neurol. Sci. 317 2012 103 105
42. F.D. Lublin, S.S. Cofield, G.R. Cutter, R. Conwit, P.A. Narayana, F. Nelson, A.R. Salter, T. Gustafson, and J.S. Wolinsky CombiRx Investigators. Randomized study combining interferon and glatiramer acetate in multiple sclerosis Ann. Neurol. 73 3 2013 327 340
43. M.J. Magraner, F. Coret, and B. Casanova The effect of intravenous immunoglobulin on neuromyelitis optica Neurologia 28 2013 65 72
44. R.N. Mandler, W. Ahmed, and J.E. Dencoff Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine Neurology 51 1998 1219 1220
45. M.A. Mealy, D.M. Wingerchuk, J. Palace, B.M. Greenberg, and M. Levy Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy JAMA Neurol. 71 2014 324 330
46. J.T. Merrill, C.M. Neuwelt, D.J. Wallace, and et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial Arthritis Rheum 62 2010 222 233
47. D.D. Mikol, F. Barkhof, P. Chang, P.K. Coyle, D.R. Jeffery, S.R. Schwid, B. Stubinski, and B. Uitdehaag Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs glatiramer acetate in relapsing MS disease [REGARD] study): a multicentre, randomised, parallel, open-label trial Lancet Neurol. 7 10 2008 903 914
48. A. Minegar, and W.A. Sheremata Treatment of Devic's disease with methotrexate and prednisone Int. J. MS Care 2 2000 43 49
49. J.H. Noseworthy, G.C. Ebers, M.K. Vandervoort, R.E. Farquhar, E. Yetisir, and R. Roberts The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial Neurology 44 1 1994 16 20
50. P. O'Connor, M. Filippi, B. Arnason, G. Comi, S. Cook, D. Goodin, H.P. Hartung, D. Jeffery, L. Kappos, F. Boateng, V. Filippov, M. Groth, V. Knappertz, C. Kraus, R. Sandbrink, C. Pohl, T. Bogumil, BEYOND Study Group, P. O'Connor, M. Filippi, B. Arnason, S. Cook, D. Goodin, H.P. Hartung, L. Kappos, D. Jeffery, and G. Comi 250 microg or 500 microg interferon beta-1b vs. 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study Lancet Neurol. 8 10 2009 889 897
51. C. Papeix, J.S. Vidal, J. de Seze, C. Pierrot-Deseilligny, A. Tourbah, B. Stankoff, C. Lebrun, T. Moreau, P. Vermersch, B. Fontaine, O. Lyon-Caen, and O. Gout Immunosuppressive therapy is more effective than interferon in neuromyelitis optica Mult. Scler. 13 2 2007 256 259
52. H.L. Pellkofer, M. Krumbholz, A. Berthele, and et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab Neurology 76 2011 1310 1315
53. S.J. Pittock, V.A. Lennon, A. McKeon, J. Mandrekar, B.G. Weinshenker, C.F. Lucchinetti, O. O'Toole, and D.M. Wingerchuk Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study Lancet Neurol. 12 2013 554 562
54. R.S. Ramanathan, K. Malhotra, and T. Scott Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate BMC Neurol. 15 2014 14 51
55. J.E. Rossouw, G.L. Anderson, R.L. Prentice, A.Z. LaCroix, C. Kooperberg, M.L. Stefanick, R.D. Jackson, S.A. Beresford, B.V. Howard, K.C. Johnson, J.M. Kotchen, and J. Ockene Writing Group for the Women's Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial JAMA 288 3 2002 321 333
56. B.H. Rovin, R. Furie, K. Latinis, and et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study Arthritis Rheum. 64 2012 1215 1226
57. R.A. Rudick, W.H. Stuart, P.A. Calabresi, C. Confavreux, S.L. Galetta, E.W. Radue, F.D. Lublin, B. Weinstock-Guttman, D.R. Wynn, F. Lynn, M.A. Panzara, and A.W. Sandrock SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis New Engl. J. Med. 354 9 2006 911 923
58. D.L. Sackett, W.M. Rosenberg, J.A. Gray, R.B. Haynes, and W.S. Richardson Evidence based medicine: what it is and what it isn't BMJ 312 7023 1996 71 72
59. M.A. Sahraian, Z. Moinfar, S. Khorramnia, and M.M. Ebrahim Relapsing neuromyelitis optics: demographic and clinical features in Iranian patients Eur. J. Neurol. 17 2010 794 799
60. D.B. Sanders, I.K. Hart, R. Mantegazza, S.S. Shukla, Z.A. Siddiqi, M.H. De Baets, A. Melms, M.W. Nicolle, N. Solomons, and D.P. Richman An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis Neurology 71 6 2008 400 406
61. J. Sellner, M. Boggild, M. Clanet, R.Q. Hintzen, Z. Illes, X. Montalban, R.A. Du Pasquier, C.H. Polman, P.S. Sorensen, and B. Hemmer EFNS guidelines on diagnosis and management of neuromyelitis optica Eur. J. Neurol. 17 8 2010 1019 1032
62. J. Shimizu, Y. Hatanaka, M. Hasegawa, A. Iwata, I. Sugimoto, H. Date, J. Goto, T. Shimizu, M. Takatsu, Y. Sakurai, H. Nakase, Y. Uesaka, H. Hashida, K. Hashimoto, T. Komiya, and S. Tsuji IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum Neurology 75 16 2010 1423 1427
63. M.J. Stampfer, and G.A. Colditz Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence Prev. Med. 20 1 1991 47 63
64. Dirk C. Strauss, and J. Meirion Thomas J. Clin. Oncol. 27 32 2009 e192 e193
65. The International Stroke Trial A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group Lancet 349 9065 1997 1569 1581
66. The Ischemic Optic Neuropathy Decompression Trial Research Group Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful: results of the Ischemic Optic Neuropathy Decompression Trial (IONDT) JAMA 273 1995 625 632
67. Y. Warabi, Y. Matsumoto, and H. Hayashi Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination J. Neurol. Sci. 252 1 2007 57 61
68. B. Weinstock-Guttman, M. Ramanathan, N. Lincoff, and et al. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic's disease) Arch. Neurol. 63 2006 957 963
69. D.M. Wingerchuk, W.F. Hogancamp, P.C. O'Brien, and B.G. Weinshenker The clinical course of neuromyelitis optica (Devic's syndrome) Neurology 53 5 1999 1107 1114
70. H. Yaguchi, K. Sakushima, I. Takahashi, and et al. Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder Intern. Med. 52 2013 969 972
71. C.-S. Yang, L. Yang, T. Li, and et al. Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica Neurology 81 2013 710 713